Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.
By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies.
Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies.
Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Location: United States, California, Hayward
Employees: 11-50
Total raised: $1.02B
Founded date: 2019
Investors 7
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.02.2025 | Series D | $351M | - |
| 07.01.2022 | Series B | $518M | - |
| 06.05.2021 | Series A | $148M | - |
Mentions in press and media 22
| Date | Title | Description |
| 16.04.2025 | Bauplan Launches With $7.5 Million in Seed to Bring AI & Data Infrastructure Into Software Engineering | New Serverless Platform Makes AI and Data Applications as Simple as Writing Code, Backed by Innovation Endeavors SAN FRANCISCO–(BUSINESS WIRE)–April 16, 2025– Bauplan, a Python-first serverless data platform that transforms complex infrastr... |
| 11.03.2025 | February's Investment Landscape: A Tale of Giants and Newcomers | February 2025 was a month of contrasts in the U.S. investment scene. While some venture capital firms took a breather, others surged ahead, making waves with significant funding rounds. The month was short, but the activity was anything but... |
| 10.03.2025 | Most-Active US Investors In February: General Catalyst Goes Big In Slow Month | 1 Shares Email Facebook Twitter LinkedIn This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 05.03.2025 | Startup Funding Slows In February Amid Exit Uncertainty | 7 Shares Email Facebook Twitter LinkedIn Global venture funding totaled $19 billion in February, marking one of the slowest months for startup investment in the past year, according to Crunchbase data. AI and healthcare were the two leading... |
| 28.02.2025 | Eikon Therapeutics Secures $350.7 Million to Propel Drug Development | Eikon Therapeutics is on the rise. The Hayward, California-based biotechnology company recently announced a significant milestone: a $350.7 million Series D funding round. This influx of capital is not just a number; it’s a lifeline for inn... |
| 27.02.2025 | Eikon Therapeutics Raises $350.7M in Series D Funding | Eikon Therapeutics, a Hayward, CA-based pivotal-stage biotechnology company for drug discovery and development, raised $350.7M in Series D funding. The investment syndicate was composed of mutual funds, sovereign wealth funds, and healthcar... |
| 27.02.2025 | Biotech Startup Eikon Therapeutics Locks Up Massive $351M Series D | 3 Shares Email Facebook Twitter LinkedIn Startup Eikon Therapeutics raised one of the biggest biotech rounds thus far in this young year. The Hayward, California-based drug startup closed on nearly $351 million in a Series D from the likes ... |
| 26.02.2025 | Eikon Therapeutics: $350.7 Million (Series D) Raised For Advancing Clinical-Stage Programs | Eikon Therapeutics, a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, announced the initial closing of a $350.7 million Seri... |
| 10.01.2025 | The Case For Revenue-Focused Platforms In The Life Sciences | 5 Shares Email Facebook Twitter LinkedIn By Caleb Appleton Having invested in the Techbio space since before it had a name, I’ve seen life sciences investors steer founders toward a therapeutics pipeline in hopes of securing the payout of a... |
| 02.06.2023 | Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline | New assets establish foundation for Eikon’s expanding pipeline of in-house and acquired drug candidates with applications in oncology and other therapeutic areas Eikon’s world-class clinical team brings deep expertise in pipeline developmen... |
Show more